Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
BIOMARIN PHARMACEUTICAL INC | Director | Common Stock | 6,900 | $532 K | $77.05 | May 21, 2024 | Direct |
Enovis CORP | Director | Common stock, par value $0.001 | 8,257 | $511 K | $61.84 | May 20, 2024 | Direct |
Option Care Health, Inc. | Director | Common Stock | 7,056 | $228 K | $32.34 | May 15, 2024 | Direct |
Hill-Rom Holdings, Inc. | SVP, Chief Financial Officer | Common Stock | 0 | $155.73 | Dec 13, 2021 | Direct | |
Hill-Rom Holdings, Inc. | SVP, Chief Financial Officer | Performance-Based Restricted Stock Units (11/06/2019) | 0 | Dec 13, 2021 | Direct | ||
Hill-Rom Holdings, Inc. | SVP, Chief Financial Officer | Performance-Based Restricted Stock Units (11/11/2020) | 0 | Dec 13, 2021 | Direct | ||
Hill-Rom Holdings, Inc. | SVP, Chief Financial Officer | Restricted Stock Units (11/06/2019) | 0 | Dec 13, 2021 | Direct | ||
Hill-Rom Holdings, Inc. | SVP, Chief Financial Officer | Restricted Stock Units (11/10/2021) | 0 | Dec 13, 2021 | Direct | ||
Hill-Rom Holdings, Inc. | SVP, Chief Financial Officer | Restricted Stock Units (11/11/2020) | 0 | Dec 13, 2021 | Direct | ||
Hill-Rom Holdings, Inc. | SVP, Chief Financial Officer | Employee Stock Option (Right to Buy) | 0 | $61.86 | Dec 13, 2021 | Direct | |
Syneos Health, Inc. | Director | Class A Common Stock | 0 | $43.00 | Sep 28, 2023 | Direct | |
Turning Point Therapeutics, Inc. | Director | Stock Option (right to buy) | 0 | Aug 17, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
BMRN | BIOMARIN PHARMACEUTICAL INC | May 21, 2024 | 1 | 0 | 4 | May 23, 2024 | Director |
ENOV | Enovis CORP | May 20, 2024 | 1 | 0 | 4 | May 22, 2024 | Director |
OPCH | Option Care Health, Inc. | May 15, 2024 | 1 | 0 | 4 | May 17, 2024 | Director |
OPCH | Option Care Health, Inc. | Apr 1, 2024 | 1 | 0 | 4 | Apr 3, 2024 | Director |
OPCH | Option Care Health, Inc. | Jan 2, 2024 | 0 | 0 | 3 | Jan 9, 2024 | Director |
BMRN | BIOMARIN PHARMACEUTICAL INC | Dec 27, 2023 | 1 | 0 | 4 | Dec 28, 2023 | Director |
BMRN | BIOMARIN PHARMACEUTICAL INC | Dec 27, 2023 | 0 | 0 | 3 | Dec 28, 2023 | Director |
SYNH | Syneos Health, Inc. | Sep 28, 2023 | 2 | -151,446 | 4 | Sep 28, 2023 | Director |
SYNH | Syneos Health, Inc. | May 25, 2023 | 1 | 0 | 4 | May 30, 2023 | Director |
ENOV | Enovis CORP | May 16, 2023 | 2 | 0 | 4 | May 18, 2023 | Director |
TPTX | Turning Point Therapeutics, Inc. | Aug 17, 2022 | 1 | 0 | 4 | Aug 17, 2022 | Director |
ENOV | Enovis CORP | Jun 7, 2022 | 3 | 0 | 4 | Jun 9, 2022 | Director |
SYNH | Syneos Health, Inc. | May 25, 2022 | 1 | 0 | 4 | May 27, 2022 | Director |
XRAY | DENTSPLY SIRONA Inc. | May 6, 2022 | 0 | 0 | 3 | May 13, 2022 | Interim CFO |
ENOV | Enovis CORP | Apr 4, 2022 | 0 | 0 | 3 | Apr 8, 2022 | Director |
SYNH | Syneos Health, Inc. | Jan 18, 2022 | 1 | 0 | 4 | Jan 20, 2022 | Director |
SYNH | Syneos Health, Inc. | Jan 15, 2022 | 0 | 0 | 3 | Jan 20, 2022 | Director |
HRC | Hill-Rom Holdings, Inc. | Dec 13, 2021 | 9 | -2,516,747 | 4 | Dec 15, 2021 | SVP, Chief Financial Officer |
HRC | Hill-Rom Holdings, Inc. | Dec 6, 2021 | 7 | -255,397 | 4 | Dec 8, 2021 | SVP, Chief Financial Officer |
HRC | Hill-Rom Holdings, Inc. | Nov 12, 2021 | 3 | -108,422 | 4 | Nov 16, 2021 | SVP, Chief Financial Officer |
HRC | Hill-Rom Holdings, Inc. | Nov 10, 2021 | 1 | 0 | 4 | Nov 12, 2021 | SVP, Chief Financial Officer |
HRC | Hill-Rom Holdings, Inc. | Nov 8, 2021 | 3 | -87,005 | 4 | Nov 10, 2021 | SVP, Chief Financial Officer |
HRC | Hill-Rom Holdings, Inc. | Nov 1, 2021 | 2 | -481,337 | 4 | Nov 3, 2021 | SVP, Chief Financial Officer |